BiTE antibodies could unlock transplants for 'Incompatible' kidney patients

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants aged 18 to 65 years. * Diagnosis of end-stage kidney disease and being evaluated for or awaiting kidney transplantation. * Calculated panel-reactive antibody level (cPRA) ≥90% and a kidney transplant waiting time of ≥5 years. * Previous treatment with a conventional desensitization regimen based on intravenous immunoglobulin and/or plasma exchange, with or without rituximab, with traceable medical records. * Persistent cPRA ≥90% or unacceptable HLA antibodies after conventional desensitization, resulting in failure to meet the immunological criteria for kidney transplantation. * Adequate nonrenal organ function to tolerate the study treatment, including left ventricular ejection fraction \>50%, resting oxygen saturation \>94%, AST and ALT \<3 times the upper limit of normal, total bilirubin \<34.2 μmol/L, and no active infection. * Ability to understand the study procedures, provide written informed consent, and comply with study treatment and follow-up requirements. Exclusion Criteria: * Inability to understand or comply with the study protocol or follow-up schedule. * Known or suspected hereditary complement deficiency. * Clinically significant central nervous system disease, including epilepsy, psychotic disorder, organic brain syndrome, cerebrovascular accident, encephalitis, central nervous system vasculitis, or cranial neuropathy requiring intervention. * AST, ALT, or GGT \>3 times the upper limit of normal, or alkaline phosphatase or total bilirubin \>1.5 times the upper limit of normal. * Acute myocardial infarction or unstable angina within 6 months before screening, severe cardiac arrhythmia, or New York Heart Association class III or IV heart failure. * Uncontrolled acute or chronic disease unrelated to end-stage kidney disease that may impair tolerance to study treatment. * Active or uncontrolled infection requiring systemic treatment. * Human immunodeficiency virus infection or uncontrolled active hepatitis B or hepatitis C infection. * Participation in another interventional clinical study within 3 months before screening or planned concurrent participation in another interventional study. * Previous treatment with another T-cell engager or bispecific T-cell-redirecting therapy. * Known severe hypersensitivity to blinatumomab, teclistamab, or any of their excipients. * Active malignancy. * Pregnancy, breastfeeding, or planned pregnancy during the study period. * Previous bone marrow transplantation, hematopoietic stem cell transplantation, or solid-organ transplantation other than kidney transplantation. * Receipt of a live vaccine within 30 days before screening or planned receipt of a live vaccine during study treatment. * Any other clinically significant condition that, in the investigator's judgment, may increase participant risk, interfere with study procedures, or affect safety or efficacy assessments.